Search

USPTO Grants JBKLAB Cancer Treatment Patent US12605382B2

The USPTO granted US Patent 12605382B2 to JBKLAB Co., Ltd. for a pharmaceutical composition containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as an active ingredient, classified under CPC A61P 35/00 for cancer treatment. The patent, filed on May 3, 2022, contains 12 claims and covers the use of the compound alone and in combination with radiotherapy or other anticancer drugs.